We observed a heterogeneous βAR expression and response to β‐blocker therapy in the tested multiple myeloma patients’ samples, which could potentially be attributed to differences in disease stage, tumor progression, and therapy, as already reported for other cancer types [30, 31]. Here, ADRB2 is linked to plasma cell myeloma.